# Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone

> **NCT00542529** · PHASE1,PHASE2 · COMPLETED · sponsor: **HiberCell, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Imprime PGG TM for Injection

## Key facts

- **NCT ID:** NCT00542529
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2007-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542529, "Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00542529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*